TAS-102, Irinotecan, and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO), A Phase II Clinical Trial. ClinicalTrials.gov NCT04109924
RNA-seq (gene expression) · human · 34 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Colorectal cancerThis series is part of our curated briefing on it.
- Samples
- 34 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trialBritish journal of cancer · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE275628_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1152270 and SRA study SRP528532. Searching any of these in the dataset finder brings you back here.
The grouping that defines any comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Sample titles run patient 1 … patient 34 and carry no group information.
- GSM8481280 patient 1
- GSM8481281 patient 2
- GSM8481282 patient 3
- GSM8481283 patient 4
- GSM8481284 patient 5
- GSM8481285 patient 6
- GSM8481286 patient 7
- GSM8481287 patient 8
- GSM8481288 patient 9
- GSM8481289 patient 10
- GSM8481290 patient 11
- GSM8481291 patient 12
- GSM8490318 patient 13
- GSM8490319 patient 14
- GSM8490320 patient 15
- GSM8490321 patient 16
- GSM8490322 patient 17
- GSM8490323 patient 18
- GSM8490324 patient 19
- GSM8490325 patient 20
- GSM8490326 patient 21
- GSM8490327 patient 22
- GSM8490328 patient 23
- GSM8490329 patient 24
- GSM8490330 patient 25
- GSM8490331 patient 26
- GSM8490332 patient 27
- GSM8490333 patient 28
- GSM8490334 patient 29
- GSM8490335 patient 30
- GSM8490336 patient 31
- GSM8490337 patient 32
- GSM8490338 patient 33
- GSM8490339 patient 34
- GSE250000 Bulk RNA-sequencing of transduced colorectal cancer cell line HCT-116 and breast cancer cell line MCF-7 overexpressing full-lenght p53β or p53β-stop-lost. 4 samples same disease briefing · shares colorectal
- GSE12032 Inherent gene signature of stage II and III colorectal cancer leads in individual recurrence 198 samples same disease briefing · shares colorectal
- GSE110009 Single cell transcriptome landscape of primary and metastatic tumor in colon cancer 76 samples same disease briefing · shares metastatic
- GSE109308 Single-cell transcriptomic survey of adenomatous polyposis patients with germline APC mutations 97 samples same disease briefing
- GSE196576 Tumor immunogenomic features determine outcomes in metastatic colorectal cancer patients treated with standard-of-care combinations of bevacizumab and cetuximab 579 samples shares bevacizumab, metastatic, colorectal
- GSE273769 The PLK1 Inhibitor Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-line Treatment of KRAS-mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. 24 samples shares bevacizumab, metastatic, colorectal
- GSE307398 Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer 12 samples shares bevacizumab, metastatic, colorectal
- GSE307937 PKM2 lactylation promotes colorectal cancer vasculogenic mimicry and resistance to bevacizumab treatment by facilitating FOSL1 super-enhancer formation [RNA-Seq] 6 samples shares bevacizumab, colorectal
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.